Effect of metformin on inflammation and bone damage in a rat model of medication‐related osteonecrosis of the jaw
Authors:
- Liviane Maria Alves RabeloLRLiviane Maria Alves Rabelo
- Mariana Vasconcelos GuimarãesMGMariana Vasconcelos Guimarães
- Aurilene Gomes CajadoACAurilene Gomes Cajado
- José Vitor Mota LemosJLJosé Vitor Mota Lemos
- Felipe Domingos de SousaFSFelipe Domingos de Sousa
- Nylane Maria Nunes AlencarNANylane Maria Nunes Alencar
- Vilma de LimaVLVilma de Lima
- Paulo Goberlânio de Barros SilvaPSPaulo Goberlânio de Barros Silva
- Ana Paula Negreiros Nunes AlvesAAAna Paula Negreiros Nunes Alves
- Deysi Viviana Tenazoa WongDeysi Viviana Tenazoa Wong
- Roberto César Pereira Lima‐JúniorRoberto César Pereira Lima‐Júnior
Open Access
- 4 December 2025
- journal article
- Published by Wiley in European Journal of Oral Sciences
- Vol. 134 (1) , e70056
Abstract
This study investigated how chronic metformin administration modulates the cellular profile and inflammatory markers in a zoledronic acid‐based rat model of medication‐related osteonecrosis of the jaw (MRONJ). Male Wistar rats were allocated to different treatments: (i) naïve, (ii) MRONJ (zoledronic acid, 0.2 mg/kg, i.v. on days 0, 7, 14, and 49), or (iii) MRONJ + metformin (250 mg/kg, by gavage, daily for 70 days). All rats had the inferior first molar extracted on day 42. Mandibular arches were harvested for analyzing their gums on day 70. Additionally, RAW 264.7 cells were incubated with zoledronic acid or metformin for cell viability tests and analysis of interleukin‐1β (IL‐1β) production. MRONJ was characterized by increased numbers of empty osteocyte lacunae, osteoclasts, and apoptotic osteoclasts, and by high expression of tartrate‐resistant acid phosphatase (TRAP) and F4/80 (a macrophage marker). Zoledronic acid‐incubated RAW 264.7 macrophages showed increased IL‐1β expression. Metformin reduced the number of empty bone lacunae, apoptotic osteoclasts, leukocyte infiltrate, and F4/80 positive cells in the alveolar bone. It increased TRAP expression levels without altering the number of osteoclasts. Metformin also reduced the myeloperoxidase activity and decreased IL‐1β levels in vitro. In conclusion, metformin reduced the severity of MRONJ by mitigating the inflammatory response.Keywords
Funding Information
- Fundação Cearense de Apoio ao Desenvolvimento Científico e Tecnológico
This publication has 43 references indexed in Scilit:
- Zoledronate Promotes Peri-Implant Osteogenesis in Diabetic Osteoporosis by the AMPK PathwayCalcified Tissue International, 2023
- Roles of osteoclasts in alveolar bone remodelingGenesis, 2022
- Brain Boron Level, DNA Content, and Myeloperoxidase Activity of Metformin-Treated Rats in Diabetes and Prostate Cancer ModelBiological Trace Element Research, 2021
- Influence of the cumulative effect of zoledronic acid on periodontal microcirculation in ratsOral and Maxillofacial Surgery, 2021
- Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With CancerJAMA Oncology, 2021
- Bisphosphonate-related osteonecrosis induced change in alveolar bone architecture in rats with participation of Wnt signalingClinical Oral Investigations, 2020
- Effects of dexamethasone and nimesulide on bisphosphonate-related osteonecrosis of the jaw: An experimental studyArchives of Oral Biology, 2017
- Effect of different doses of zoledronic acid in establishing of bisphosphonate-related osteonecrosisArchives of Oral Biology, 2015
- Bisphosphonate Induces Osteonecrosis of the Jaw in Diabetic Mice via NLRP3/Caspase-1-Dependent IL-1β MechanismJournal of Bone and Mineral Research, 2015
- Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International ConsensusJournal of Bone and Mineral Research, 2014